findmyKOL

Nicholas Vogelzang, MD

Enriched profile

Medical Oncologist and Chairman of Medical Oncology, Comprehensive Cancer Centers of Nevada; Site Research Leader, US Oncology Research (position held until his death on September 20, 2022, deceased, not an active current role) · Comprehensive Cancer Centers of Nevada

ORCID↗NPI↗
✓ Full profile
RegionLas Vegas, NV · WestSpecialtyHematology / OncologyFocusProstate Cancer Treatment and Research+4
Last active 2023findmyKOL type: NationalLatest publication2023Online presenceNone verifiedPayments2021–2022NIH fundingNone on fileWhy? →

Nicholas Vogelzang is Medical Oncologist and Chairman of Medical Oncology, Comprehensive Cancer Centers of Nevada; Site Research Leader, US Oncology Research (position held until his death on September 20, 2022, deceased, not an active current role) at Comprehensive Cancer Centers of Nevada. OpenAlex indexes 1,129 publications with 69,644 citations (h-index 115); ClinicalTrials.gov lists 2 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory. Clarivate lists Nicholas Vogelzang as a Highly Cited Researcher (Clinical Medicine, 2020-2024).

Data verified 14 Aug 2026

Overview

Updated 14 Oct 2026

Nicholas J. Vogelzang is Medical Oncologist and Chairman of Medical Oncology, Comprehensive Cancer Centers of Nevada. The public record shows 1,129 publications with 69,644 citations (h-index 115), centered on Prostate Cancer Treatment and Research, Renal cell carcinoma treatment, Bladder and Urothelial Cancer Treatments. It also documents an investigator role on 2 registered clinical trials.

  • Most recent indexed publication: 2023 · Journal of clinical oncology
  • Top research focus: Prostate Cancer Treatment and Research
  • 2 registered trials on ClinicalTrials.gov

Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Kidney Cancer / RCC1 trialProstate Cancer1 trialKidney Neoplasms1 trialBladder / Urothelial Cancer

Research focus

OpenAlex concept fingerprint
Prostate Cancer Treatment and ResearchRenal cell carcinoma treatmentBladder and Urothelial Cancer TreatmentsRadiopharmaceutical Chemistry and ApplicationsCancer Immunotherapy and Biomarkers

Drugs & molecules

across trials, industry payments and publications
Keytrudageneric · PembrolizumabClinical trials—Industry payments4Publications4Xofigogeneric · RadiumClinical trials—Industry payments3Publications2Rubracageneric · RucaparibClinical trials—Industry payments1Publications3Jevtanageneric · CabazitaxelClinical trials—Industry payments20Publications—Erleadageneric · ApalutamideClinical trials—Industry payments16Publications—Balversageneric · ErdafitinibClinical trials—Industry payments7Publications—Lenvimageneric · LenvatinibClinical trials—Industry payments5Publications—Lynparzageneric · OlaparibClinical trials—Industry payments4Publications—Orgovyxgeneric · RelugolixClinical trials—Industry payments4Publications—Xtandigeneric · EnzalutamideClinical trials—Industry payments3Publications—Bavenciogeneric · AvelumabClinical trials—Industry payments2Publications—Bosulifgeneric · BosutinibClinical trials—Industry payments2Publications—

Works with

trial sponsors and companies reporting payments
Genzyme CorporationClinical trials—Industry payments20Janssen Biotech, Inc.Clinical trials—Industry payments16Merck Sharp & Dohme CorporationClinical trials—Industry payments6Pfizer Inc.Clinical trials—Industry payments6Bayer HealthCare Pharmaceuticals Inc.Clinical trials—Industry payments5AstraZeneca Pharmaceuticals LPClinical trials—Industry payments4Eisai Inc.Clinical trials—Industry payments4Advanced Accelerator ApplicationsClinical trials—Industry payments3Gilead Sciences, Inc.Clinical trials—Industry payments3Myovant Sciences Inc.Clinical trials—Industry payments3Seagen Inc.Clinical trials—Industry payments3Astellas Pharma US IncClinical trials—Industry payments2Aveo Pharmaceuticals, Inc.Clinical trials—Industry payments2Celgene CorporationClinical trials—Industry payments2Dendreon Pharmaceuticals LLCClinical trials—Industry payments2AEterna ZentarisClinical trials1Industry payments—Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trials—Industry payments1Clovis Oncology, Inc.Clinical trials—Industry payments1Exelixis Inc.Clinical trials—Industry payments1Helsinn Healthcare SAClinical trials—Industry payments1Merck Sharp & Dohme LLCClinical trials—Industry payments1Novartis Pharmaceuticals CorporationClinical trials—Industry payments1SOTIO a.s.Clinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,129publications

Distinct works indexed by OpenAlex, matched via ORCID; 8 in PubMed.

69,644citations

Total citations across indexed works.

115h-index

Hirsch index (OpenAlex). i10-index 511.

Clinical & industry

trials, payments and federal funding
2clinical trials

Investigator role on registered studies.

View trials ↓
21companies · 2021–2022

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 14 Oct 2026

Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

21 companies reported payments to CMS in program years 2021–2022. These are public disclosures, not judgments. The latest:

All 26 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2022)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Genitourinary & hormones

    34.3%
    Androgen33.9%
    Testosterone cypionate100%
    Part B, office-administered≥19 patients
    5-alpha Reductase Inhibitor0.2%
    Finasteride100%
    Part D≥23 patients

    + 2 more classes in this area

  • Metabolism & gastrointestinal

    29%
    Other antiemetics26.8%
    Fosaprepitant100%
    Part B, office-administered≥24 patients
    Serotonin-3 Receptor Antagonist1.9%
    Palonosetron hcl100%
    Part B, office-administered≥26 patients

    + 2 more classes in this area

  • Blood & clotting

    24.7%
    Erythropoiesis-stimulating Agent24.6%
    Darbepoetin alfa100%
    Part B, office-administered≥14 patients
    Factor Xa inhibitor0.1%
    Eliquis100%
    Part D<11 patients
All 10 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 14 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 8 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
    3,395 citations2017
    doi.org ↗
  2. 02
    Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
    3,348 citations2013
    doi.org ↗
  3. 03
    Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
    3,071 citations2003
    doi.org ↗
  4. 04
    Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
    2,840 citations2015
    doi.org ↗
  5. 05
    Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
    2,647 citations2003
    doi.org ↗
All 1,129 cited works: search, sort and filter.Explore →

Network

Updated 14 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Ximing J. Yang153Bin Tean Teh150Richard J. Kahnoski142Troy D. Randall140Ali R. Afzal140Christos C. Zouboulis140Daniel Pauly140Seda Sancak140Alexander Unrath140Mark A. Marinella140Jonathan R. Carapetis140Jean‐Marc Nuoffer140Anushree C. Shirali140Pedro Brites140Julie Raggio140Robert J. Meislin140Daniel R. Goldstein140Annemieke M. Bams-Mengerink140Sudha K. Iyengar140Javier Rangel‐Moreno140Angela Bentivegna140Ronald J. A. Wanders140Richard J. Sugrue140Harjot K. Saini140John‐John B. Schnog140Ritva Häyrinen‐Immonen140Josef Penninger140Christian E. Elger140Alfried Kohlschütter140Andrew C. Steer140Dietmar Lohmann140Klaus Rüether140Christian G. Bien140Werner J. Heppt140Annette Cryer140Margaret R. Wallace140Oded Sperling140Victor E. A. Gerdes140Barry I. Freedman140Lidia Larizza140

Online presence

Updated 14 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Mentions by others

where others cite or feature them
  • Other

    onclive.com/authors/nicholas-j-vogelzang-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 14 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Fellowship in Medical Oncology

    University of Minnesota, Minneapolis

    1980
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthgrades.com ↗
  • MD

    University of Illinois College of Medicine (Chicago)

    1974
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthgrades.com ↗
  • Internship

    residency, and chief residency in Internal Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
  • Board Certified

    American Board of Internal Medicine, Internal Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthgrades.com ↗
  • Board Certified

    American Board of Internal Medicine, Medical Oncology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthgrades.com ↗

Editorial & leadership roles

journal and society appointments

Highly Cited Researcher

Clarivate's annual list, by award category and year
  • Clinical Medicine
    20202021202220232024
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • US Oncology Network / US Oncology Research

    Medical Director, Research Executive Committee; Associate Chair, Developmental Therapeutics and GU Committees

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cccnevada.com ↗
  • University of Nevada School of Medicine

    Clinical Professor of Medicine (concurrent with CCCN practice)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cccnevada.com ↗

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.